

# Inclusion of Women in Clinical Trials, a regulator's perspective

Christine Gispen-de Wied Science Office

regulatory science student (master Drug Innovation UU) Ngozi Aguwamba



#### **Drugs & Gender in Society**

WOMEN INC Hor ●	ne Wat we doen	Nieuws	Agenda	Doe mee!	Over ons	Contact	Zoeken	Inloggen	Registreren
WOMEN Inc. >	÷	Nieuws &	Agenda	<b>&gt;</b> :	Doe m	ee! ›		aanTafel >	



#### 6 VRAGEN OVER VROUWEN EN GENEESMIDDELEN





Wat zijn de feiten als het gaat om sekseverschillen bij geneesmiddelenonderzoek- en gebruik? Is het echt waar dat vrouwen meer medicijnen slikken dan mannen en er te weinig onderzoek wordt gedaan op vrouwen? WOMEN Inc. pleit samen met de <u>Alliantie Gender en Gezondheid</u> voor zorg op maat waar de gezondheidsverschillen tussen mannen en vrouwen worden meegenomen. Ook bij geneesmiddelen blijft dit een belangrijk onderwerp. In dit artikel zetten wij een aantal vragen en antwoorden over m/v verschillen bij medicijngebruik op een rijtje.

#### 1. Wat zijn verschillen tussen mannen en vrouwen in bijwerkingen?

• Vrouwen hebben 60% meer kans op bijwerkingen van medicijnen.

. Bii 0 van da 10 aanaamiddalan dia turaan 1007 an 2001 van da mavlet warden aahaald vanwaara amatiar




## **Drugs & Gender in Public Funding**

ZonMw	ProjectNet Vacatu	res Over ZonMw Veelgestelde vragen Contact English website
Subsidies	Onderzoek & resultaten	Actueel
Home Over ZonMw Diversiteit Gender en G	ezondheid	
Gender en G	azandhaid	
Gender en G	ezonaneia	
		Deel deze pagina 🗓 💙 📢 😒
Over dit programma		Deel deze pagina 🗊 🛇 f 😒 Inhoud van het programma
Over dit programma		



#### **Drugs & Gender in Public Funding**





C B G

#### **Drugs & Gender in Scientific Publications**

GENDER MEDICINE/VOL. 7, No. 4, 2010

Commentary

#### Sex, Gender, and Pharmaceutical Politics: From Drug Development to Marketing

**Jill A. Fisher, PhD<sup>1</sup>; and Lorna M. Ronald, PhD<sup>2</sup>** <sup>1</sup>Center for Biomedical Ethics & Society, Vanderbilt University, Nashville, Tennessee; and <sup>2</sup>Interdisciplinary Studies Program, John Jay College (City University of New York), New York, New York

**Conclusions:** Sex and gender play important roles in pharmaceutical regulation, from the design of clinical trials and the approval of new drugs to advertising and postmarketing surveillance. However, regulatory agencies pay insufficient attention to both biological sex differences and sociocultural gender norms. This disregard perpetuates inequalities by ignoring drug safety problems that predominate in women and by allowing misleading drug marketing that reinforces gender stereotypes. Recommendations have been made to improve the regulation of pharmaceuticals in regard to sex and gender. (*Gend Med.* 2010;7:357–370) © 2010 Excerpta Medica Inc.

5



B

c B G

#### **Drugs & Gender Agenda MEB** (2017)

 $\underbrace{\mathbf{C} \quad \mathbf{B} \quad \mathbf{G}}_{M \quad E \quad B}$ College ter Beoordeling van Geneesmiddelen

Home > Voor mensen > Zorgverleners >

Q

#### Man-vrouw verschillen en geneesmiddelen

Voordat geneesmiddelen op de markt komen, onderzoeken de fabrikanten de werking hiervan bij de patiëntengroep waarvoor het middel is bedoeld. Als geneesmiddelen in Nederland bijvoorbeeld ook aan vrouwen worden voorgeschreven, dan moeten deze ook bij hen zijn onderzocht. Het CBG laat alleen geneesmiddelen toe als deze voldoende zijn onderzocht en als deze goed genoeg werken en de bijwerkingen acceptabel zijn.

De biologische verschillen tussen mannen en vrouwen zijn belangrijk voor de diagnose, behandeling, het verloop van verschillende ziekten en medische condities. Daarom besteedt het CBG bij de beoordeling en bewaking van geneesmiddelen onder meer aandacht aan de verschillen en overeenkomsten tussen mannen en vrouwen. Het CBG slaat deze kennis en gegevens over geneesmiddelen op in de registratiedossiers van geneesmiddelen.



c B G


#### **Drugs & Gender Agenda MEB**

3 small scale regulatory science projects

- External validity of B/R decisions?
  - A cross-sectional survey of drug dossiers and phase 3 clinical trials
    - Infectious Disease
    - Central Nervous System
    - Cardiovascular
    - Metabolic
  - Central procedures 2011-2015
  - Source material: EPAR/SmPC & MEB database
- Recommendations for Industry
  - Attention for gender in clinical guidelines
- Gender specific PK/PD in the label (e.g. dosing)
  - A cross-sectional survey of drug dossiers and phase 1 clinical studies




#### Disease Domains (4), Drugs (30), Trials (236) & Patients (152.792)






#### Disease Domains (4), Drugs (30), Trials (236) & Patients (152.792)





#### **Inclusion of women in phase 3 Clinical Trials**





- Women are included in phase 3 clinical trials: external validity of trial data is safeguarded for licensing purposes.
- Gender disproportionality is **two sided**: skewed towards men in the cardiovascular domain and schizophrenia, skewed towards women in hepatitis C and thrombosis:




CBG ME<sup>B</sup>

## **Effect size by Gender**

Indication	Trial Objective
НерС	% subj with SVR
HIV	% subj with HIV-1 RNA<50 copies/ml
Depr	change from baseline HAM-D or MADRS
Sx	relapse rate as HR
Epilepsy	% change from baseline in seizure frequency
Hyperchol	change from baseline in LDL
HF	HR/RR to CV hosp or death
Thromb	HR/RR to CV hosp or death
AF	HR/RR to CV hosp or death
Diabetes	change from aseline HbA1c



## **Effect size by Gender**





B


с B G


- Women are included in phase 3 clinical trials: external validity of trial data is safeguarded for licensing purposes.
- Gender disproportionality is **two sided**: skewed towards men in the cardiovascular domain and schizophrenia, skewed towards women in hepatitis C and thrombosis
- Effect sizes are similar in men and women; variation at the group level is substantial: gender is a personalized factor



CBG ME<sup>B</sup>


#### Safety reporting







## Safety reporting





с B G

- Women are included in phase 3 clinical trials: external validity of trial data is safeguarded for licensing purposes.
- Gender disproportionality is **two sided**: skewed towards men in the cardiovascular domain and schizophrenia, skewed towards women in hepatitis C and thrombosis
- Effect sizes are similar in men and women; variation at the group level is substantial: gender is a personalized factor
- Safety reporting is gender sensitive: the proportion women reporting on safety is higher and consistent on drug and placebo



#### **Recommendations for Industry**

Guideline 💌	Year 🔽	Gender 🚽 💌	Cinical 🔹	Pharmacol 💌
HepC	2009	no		
Diabetes	2012	yes	study population	
Depr	2013	no		
Sx	2013	yes	study population	
AF	2014	yes	study population	
HF	2015	yes	outcome/cardiac events	
HIV	2017	yes	treatment naïve pts	PK/PD
Hyperchol	2017	yes	study population	PK/PD
Thromb	2017	yes	study population/statistics	



R

с B G

- Women are included in phase 3 clinical trials: external validity of trial data is safeguarded for licensing purposes.
- Gender disproportionality is **two sided**: skewed towards men in the cardiovascular domain and schizophrenia, skewed towards women in hepatitis C and thrombosis
- Effect sizes are similar in men and women; variation at the group level is substantial: gender is a personalized factor
- Safety reporting is gender sensitive: the proportion women reporting on safety is higher and consistent on drug and placebo
- Information in guidelines is present, but sparse

#### Inclusion of women in clinical trials


CBG ME<sup>B</sup>

#### **Phase 1 studies**

Selection of Drug candidate	<ul> <li>Cross-sectional across 4 disease domains: Infectious disease-CNS-cardiovascular-metabolic</li> <li>Years (2011-2015: central procedures</li> <li>Source material: EPAR/SmPC &amp; CBG database</li> </ul>	
Phase I: Screening/Reviewing for PK parameters and dose recommendation based on gender and body weight from SmPc.	• Section 4.2 • Section 5.2	
Screening/Reviewing for PK parameters and dose recommendation based on gender and body weight from Scientific discussion.	<ul> <li>Section 2.4.2</li> <li>Section 2.4.4</li> <li>Section 3</li> </ul>	
Screening/Reviewing for PK parameters and dose recommendation based on gender and body weight from Dossiers (ICI).	<ul> <li>Section 2.5.3</li> <li>Section 2.7.2</li> <li>Section 5.3.3.5</li> </ul>	



#### **Gender proportionality phase 1**





## **PK/PD: information in the label**

Screening criteria	Score
Dose recommendation based on gender.	0
Dose modification based on body weight.	2
Statistically significant effect on gender, but not clinically relevant. (Daklinza, Exveria, Fycompa, Lyxumia, Multaq)	5
Statistically significant effect on body weight, but not clinically relevant. (Exveria,Harvoni , Fycompa, Eperzan,Trulicity, Lyxumia, Praluent, Multaq)	8

Screening of Drugs (SmPc and Scientific discussion)



## **PK/PD: information in the Dossier**

Screening criteria	Score
Dose recommendation based on gender.	0
Dose modification based on body weight.	0
Drugs with Number of AUC or Cmax values	22
Drugs having Clearance for gender	3
Total drugs with AUC, Cmax or clearance values	25/29



R

c B G

- Women are included in phase 3 clinical trials: external validity of trial data is safeguarded for licensing purposes.
- Gender disproportionality is **two sided**: skewed towards men in the cardiovascular domain and schizophrenia, skewed towards women in hepatitis C and thrombosis
- Effect sizes are similar in men and women; variation at the group level is substantial: gender is a personalized factor
- Safety reporting is gender sensitive: the proportion women reporting on safety is higher and consistent on drug and placebo
- Information in guidelines is present, but sparse
- Women are included in phase 1 trials, but less compared to phase 3
- PK/PD data in the label lack behind those in the dossier



C B


- Women are included in phase 3 clinical trials: external validity of trial data is safeguarded for licensing purposes.
- Gender disproportionality is two sided: skewed towards men in the cardiovascular domain and schizophrenia, skewed towards women in hepatitis C and thrombosis
- Effect sizes are similar in men and women; variation at the group level is substantial: gender is a personalized factor
- Safety reporting is gender sensitive: the proportion women reporting on safety is higher and consistent on drug and placebo
- Information in guidelines is present, but sparse
- Women are included in phase 1 trials, but less compared to phase 3
- PK/PD data in the label lack behind those in the dossier



B

с в G

#### Take Home Message: forget numbers, think big



Discuss with different stakeholders the role of gender in drug development

Create 'gender awareness' among regulators

Use dossier data to the maximum